Previous close | 4.73 |
Open | 6.20 |
Bid | 5.95 |
Ask | 6.15 |
Strike | 60.00 |
Expiry date | 2024-05-17 |
Day's range | 6.18 - 6.20 |
Contract range | N/A |
Volume | |
Open interest | 89 |
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)